By Fineline Cube 
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R²) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on compelling Phase 3 data demonstrating unprecedented efficacy improvements over standard therapy.
Regulatory Approval Details
| Parameter | Detail |
|---|---|
| Agency | European Commission (EC) |
| Product | TEPKINLY® (epcoritamab) + lenalidomide + rituximab (R²) |
| Indication | Adult patients with relapsed or refractory follicular lymphoma |
| Approval Date | 6 July 2026 |
| Molecule Type | Bispecific antibody targeting CD3 (T-cell) and CD20 (B-cell) |
| Supporting Trial | Phase 3 EPCORE FL-1 study |
Clinical Trial Results – EPCORE FL-1 Phase 3 Study
The open-label, randomized trial compared TEPKINLY + R² against R² alone in patients with R/R FL, delivering statistically significant and clinically meaningful outcomes across all key endpoints:
Primary Endpoint – Progression-Free Survival (PFS)
- 79% reduction in risk of disease progression or death (HR 0.21, 95% CI: 0.13–0.33, p<0.0001)
Secondary Endpoints
| Endpoint | TEPKINLY + R² | R² Alone | Statistical Significance |
|---|---|---|---|
| Overall Response Rate (ORR) | 96% (95% CI: 90.2–98.6) | 81% (95% CI: 72.7–87.7) | p<0.0001 |
| Complete Response (CR) Rate | 74% (181/243, 95% CI: 68.5–79.8) | 43% (106/245, 95% CI: 37.0–49.7) | p<0.0001 |
Safety Profile
- Consistent with known safety profiles of individual regimen components
- No new safety signals identified
- Manageable adverse event profile supporting outpatient administration potential
Market Context & Competitive Landscape
Follicular lymphoma represents approximately 20-30% of all non-Hodgkin lymphomas, with an estimated 15,000-20,000 new cases annually in Europe. Despite advances in treatment, R/R FL remains challenging to manage, with limited therapeutic options offering durable responses.
TEPKINLY’s approval positions AbbVie to compete directly with other bispecific antibodies in development, including Roche’s mosunetuzumab and Genmab/Janssen’s epcoritamab (different molecule), while offering superior efficacy data compared to existing standard-of-care regimens. The subcutaneous administration route provides additional convenience advantages over intravenous alternatives.
Commercial Implications
- Revenue Potential: Analysts project peak annual sales of €800-1.2 billion in the European FL indication alone
- Pricing Strategy: Expected premium pricing reflecting substantial clinical benefit and unmet medical need
- Market Access: Rapid reimbursement negotiations anticipated given magnitude of clinical benefit
- Global Expansion: U.S. FDA decision expected Q4 2026; additional regulatory submissions planned for Asia-Pacific markets
Strategic Significance for AbbVie
This approval strengthens AbbVie’s oncology portfolio beyond its flagship immunology franchise, demonstrating successful execution of its strategy to diversify revenue streams. TEPKINLY represents the company’s first approved bispecific antibody and establishes a platform for expansion into additional hematologic malignancies, with ongoing trials in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL).
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, market opportunities, and financial projections. Actual results may differ materially due to competitive pressures, regulatory requirements, market acceptance, and other risk factors detailed in AbbVie’s SEC filings.-Fineline Info & Tech